Warning: Undefined array key "mm" in /www/wwwroot/www.ai-bt.com/si.php on line 10 Deprecated: trim(): Passing null to parameter #1 ($string) of type string is deprecated in /www/wwwroot/www.ai-bt.com/si.php on line 10 Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Literature DB >> 24436312

Human epidermal growth factor receptor family-targeted therapies in the treatment of HER2-overexpressing breast cancer.

Zeynep Eroglu¹, Tomoko Tagawa, George Somlo.

Abstract

Breast cancer characterized by overexpression of human epidermal growth factor receptor 2 (HER2) has been associated with more aggressive disease progression and a poorer prognosis. Although an improved understanding of breast cancer pathogenesis and the role of HER2 signaling has resulted in significant survival improvements in the past 20 years, resistance to HER2-targeted therapy remains a concern. A number of strategies to prevent or overcome resistance to HER2-targeted therapy in breast cancer are being evaluated. This article provides a comprehensive review of (a) the role of HER2 signaling in breast cancer pathogenesis, (b) potential receptor and downstream therapeutic targets in breast cancer to overcome resistance to HER2-targeted therapy, and (c) clinical trials evaluating agents targeting one or more members of the HER family and/or downstream pathways for the treatment of breast cancer, with a focus on metastatic disease.

Entities: Disease Gene Species

Keywords: Breast cancer; Epidermal growth factor receptor; Human epidermal growth factor receptor tyrosine kinase receptor family; Tyrosine kinase inhibitor

Mesh：

Substances：

Year: 2014 PMID： 24436312 PMCID： PMC3926785 DOI： 10.1634/theoncologist.2013-0283

Source DB: PubMed Journal: Oncologist ISSN： 1083-7159

84 in total

1. High risk of recurrence for patients with breast cancer who have human epidermal growth factor receptor 2-positive, node-negative tumors 1 cm or smaller.

Authors: Ana M Gonzalez-Angulo; Jennifer K Litton; Kristine R Broglio; Funda Meric-Bernstam; Ronjay Rakkhit; Fatima Cardoso; Florentia Peintinger; Emer O Hanrahan; Aysegul Sahin; Merih Guray; Denis Larsimont; Francesco Feoli; Heidi Stranzl; Thomas A Buchholz; Vicente Valero; Richard Theriault; Martine Piccart-Gebhart; Peter M Ravdin; Donald A Berry; Gabriel N Hortobagyi
Journal: J Clin Oncol Date: 2009-11-02 Impact factor: 44.544

2. Trastuzumab emtansine for HER2-positive advanced breast cancer.

Authors: Sunil Verma; David Miles; Luca Gianni; Ian E Krop; Manfred Welslau; José Baselga; Mark Pegram; Do-Youn Oh; Véronique Diéras; Ellie Guardino; Liang Fang; Michael W Lu; Steven Olsen; Kim Blackwell
Journal: N Engl J Med Date: 2012-10-01 Impact factor: 91.245

3. Neratinib, an irreversible ErbB receptor tyrosine kinase inhibitor, in patients with advanced ErbB2-positive breast cancer.

Authors: Harold J Burstein; Yan Sun; Luc Y Dirix; Zefei Jiang; Robert Paridaens; Antoinette R Tan; Ahmad Awada; Anantbhushan Ranade; Shunchang Jiao; Gary Schwartz; Richat Abbas; Christine Powell; Kathleen Turnbull; Jennifer Vermette; Charles Zacharchuk; Rajendra Badwe
Journal: J Clin Oncol Date: 2010-02-08 Impact factor: 44.544

4. Neoadjuvant chemotherapy with trastuzumab followed by adjuvant trastuzumab versus neoadjuvant chemotherapy alone, in patients with HER2-positive locally advanced breast cancer (the NOAH trial): a randomised controlled superiority trial with a parallel HER2-negative cohort.

Authors: Luca Gianni; Wolfgang Eiermann; Vladimir Semiglazov; Alexey Manikhas; Ana Lluch; Sergey Tjulandin; Milvia Zambetti; Federico Vazquez; Mikhail Byakhow; Mikhail Lichinitser; Miguel Angel Climent; Eva Ciruelos; Belén Ojeda; Mauro Mansutti; Alla Bozhok; Roberta Baronio; Andrea Feyereislova; Claire Barton; Pinuccia Valagussa; Jose Baselga
Journal: Lancet Date: 2010-01-30 Impact factor: 79.321

5. Lapatinib versus trastuzumab in combination with neoadjuvant anthracycline-taxane-based chemotherapy (GeparQuinto, GBG 44): a randomised phase 3 trial.

Authors: Michael Untch; Sibylle Loibl; Joachim Bischoff; Holger Eidtmann; Manfred Kaufmann; Jens-Uwe Blohmer; Jörn Hilfrich; Dirk Strumberg; Peter A Fasching; Rolf Kreienberg; Hans Tesch; Claus Hanusch; Bernd Gerber; Mahdi Rezai; Christian Jackisch; Jens Huober; Thorsten Kühn; Valentina Nekljudova; Gunter von Minckwitz
Journal: Lancet Oncol Date: 2012-01-17 Impact factor: 41.316

6. Trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer.

Authors: Martine J Piccart-Gebhart; Marion Procter; Brian Leyland-Jones; Aron Goldhirsch; Michael Untch; Ian Smith; Luca Gianni; Jose Baselga; Richard Bell; Christian Jackisch; David Cameron; Mitch Dowsett; Carlos H Barrios; Günther Steger; Chiun-Shen Huang; Michael Andersson; Moshe Inbar; Mikhail Lichinitser; István Láng; Ulrike Nitz; Hiroji Iwata; Christoph Thomssen; Caroline Lohrisch; Thomas M Suter; Josef Rüschoff; Tamás Suto; Victoria Greatorex; Carol Ward; Carolyn Straehle; Eleanor McFadden; M Stella Dolci; Richard D Gelber
Journal: N Engl J Med Date: 2005-10-20 Impact factor: 91.245

7. Expression of the HER1-4 family of receptor tyrosine kinases in breast cancer.

Authors: Caroline J Witton; Jonathan R Reeves; James J Going; Timothy G Cooke; John M S Bartlett
Journal: J Pathol Date: 2003-07 Impact factor: 7.996

8. Target binding properties and cellular activity of afatinib (BIBW 2992), an irreversible ErbB family blocker.

Authors: Flavio Solca; Goeran Dahl; Andreas Zoephel; Gerd Bader; Michael Sanderson; Christian Klein; Oliver Kraemer; Frank Himmelsbach; Eric Haaksma; Guenther R Adolf
Journal: J Pharmacol Exp Ther Date: 2012-08-10 Impact factor: 4.030

9. Pharmacokinetic-pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activity.

Authors: Rakesh Kumar; Victoria B Knick; Sharon K Rudolph; Jennifer H Johnson; Renae M Crosby; Ming-Chih Crouthamel; Teresa M Hopper; Charles G Miller; Laura E Harrington; James A Onori; Robert J Mullin; Tona M Gilmer; Anne T Truesdale; Andrea H Epperly; Amogh Boloor; Jeffrey A Stafford; Deirdre K Luttrell; Mui Cheung
Journal: Mol Cancer Ther Date: 2007-07 Impact factor: 6.261

10. Cytogenetic analysis of HER1/EGFR, HER2, HER3 and HER4 in 278 breast cancer patients.

Authors: Andrea Sassen; Justine Rochon; Peter Wild; Arndt Hartmann; Ferdinand Hofstaedter; Stephan Schwarz; Gero Brockhoff
Journal: Breast Cancer Res Date: 2008-01-08 Impact factor: 6.466

22 in total

1. Measurement of Domain-Specific HER2 (ERBB2) Expression May Classify Benefit From Trastuzumab in Breast Cancer.

Authors: Daniel E Carvajal-Hausdorf; Kurt A Schalper; Lajos Pusztai; Amanda Psyrri; Konstantine T Kalogeras; Vasiliki Kotoula; George Fountzilas; David L Rimm
Journal: J Natl Cancer Inst Date: 2015-05-19 Impact factor: 13.506

2. Bruton's Tyrosine Kinase Inhibitors Prevent Therapeutic Escape in Breast Cancer Cells.

Authors: Xianhui Wang; Jason Wong; Christopher J Sevinsky; Leila Kokabee; Faiza Khan; Yan Sun; Douglas S Conklin
Journal: Mol Cancer Ther Date: 2016-06-02 Impact factor: 6.261

3. A Role for Macro-ER-Phagy in ER Quality Control.

Authors: Zhanna Lipatova; Nava Segev
Journal: PLoS Genet Date: 2015-07-16 Impact factor: 5.917

Review 4. Cardiac toxicity of trastuzumab in elderly patients with breast cancer.

Authors: Andrea Denegri; Tiziano Moccetti; Marco Moccetti; Paolo Spallarossa; Claudio Brunelli; Pietro Ameri
Journal: J Geriatr Cardiol Date: 2016-05 Impact factor: 3.327

5. Development of a test that measures real-time HER2 signaling function in live breast cancer cell lines and primary cells.

Authors: Yao Huang; David J Burns; Benjamin E Rich; Ian A MacNeil; Abhijit Dandapat; Sajjad M Soltani; Samantha Myhre; Brian F Sullivan; Carol A Lange; Leo T Furcht; Lance G Laing
Journal: BMC Cancer Date: 2017-03-16 Impact factor: 4.430

6. Sulfatase 1 (hSulf-1) reverses basic fibroblast growth factor-stimulated signaling and inhibits growth of hepatocellular carcinoma in animal model.

Authors: Gaoya Xu; Weidan Ji; Yinghan Su; Yang Xu; Yan Yan; Shuwen Shen; Xiaoya Li; Bin Sun; Haihua Qian; Lei Chen; Xiaohui Fu; Mengchao Wu; Changqing Su
Journal: Oncotarget Date: 2014-07-15

7. The SystHERs registry: an observational cohort study of treatment patterns and outcomes in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer.

Authors: Debu Tripathy; Hope S Rugo; Peter A Kaufman; Sandra Swain; Joyce O'Shaughnessy; Mohammad Jahanzeb; Ginny Mason; Mary Beattie; Bongin Yoo; Catherine Lai; Anthony Masaquel; Sara Hurvitz
Journal: BMC Cancer Date: 2014-05-02 Impact factor: 4.430